Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
764.440.02%
QQQ
715.040.02%
BTC/USD
77356.200.1921%
DIA
525.910.02%
GLD
398.290.12%
TLT
80.930.07%

Lexicon Pharmaceuticals Inc

LXRXNASDAQ
Trade with Public
Trade with Public
$2.00
-0.02-0.99%
At close: Sep 11, 5:00 PM EST
$1.98
-0.02-1%
After Hours: 7:40 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Lexicon Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Lexicon Pharmaceuticals (LXRX).

Price Target Range — 8 Quarters

Analyst Consensus — 5 Analysts

3Buy
2Hold
Consensus RatingBuy# Analysts5Avg. Consensus PT$4Upside to Avg. PT+113.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
May 11, 2026CitigroupYigal NochomovitzPT RaiseBuy$2→$3
Mar 23, 2026HC Wainwright & Co.Joseph PantginisMaintainedBuy$6
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Citigroup Maintains Buy on Lexicon Pharmaceuticals, Raises Price Target to $3.1

Citigroup analyst Yigal Nochomovitz maintains Lexicon Pharmaceuticals (NASDAQ:LXRX) with a Buy and raises the price target from $2.3 to $3.1.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Lexicon Pharmaceuticals, Maintains $6 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Lexicon Pharmaceuticals (NASDAQ:LXRX) with a Buy and maintains $6 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Lexicon Pharmaceuticals, Raises Price Target to $6

HC Wainwright & Co. analyst Joseph Pantginis maintains Lexicon Pharmaceuticals (NASDAQ:LXRX) with a Buy and raises the price target from $4 to $6.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Lexicon Pharmaceuticals, Maintains $4 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Lexicon Pharmaceuticals (NASDAQ:LXRX) with a Buy and maintains $4 price target.
Benzinga Newsdesk

PRO
Citigroup Maintains Buy on Lexicon Pharmaceuticals, Raises Price Target to $1.9

Citigroup analyst Yigal Nochomovitz maintains Lexicon Pharmaceuticals (NASDAQ:LXRX) with a Buy and raises the price target from $1.2 to $1.9.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Lexicon Pharmaceuticals, Maintains $4 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Lexicon Pharmaceuticals (NASDAQ:LXRX) with a Buy and maintains $4 price target.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved